Date: 2014-05-09
Type of information: Collaboration agreement
Compound:
Company: Pfizer (USA - NY) Global Medical Excellence Cluster - GMEC (UK)
Therapeutic area: Rare diseases
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On May 9, 2014, the Global Medical Excellence Cluster (GMEC) that includes Cambridge University, Imperial College London, King’s College London, Queen Mary University London, University College London and Oxford University announced a five year collaborative agreement with Pfizer that provides a framework for the research and development of new and innovative medicines for rare diseases. Scientists from the GMEC partners – Cambridge University, Imperial College London, King’s College London, Queen Mary University London, University College London and Oxford University – will work with Pfizer scientists on joint drug discovery programmes. The initiative will build on advances in understanding the molecular mechanisms underpinning rare diseases and will benefit from the significant progress made by the UK Government in building support for genomics research, for example the creation of Genomics England. Initial rollout of the programme has already begun. Senior Pfizer scientists, including Dr. Kevin Lee, Chief Scientific Officer of Pfizer’s Rare Disease Research Unit and GMEC CEO, Dr Jim Hagan, are visiting theGMEC Universities to launch the initiative.
Financial terms:
Latest news:
